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Abstract
High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical
setting, despite the fact that they are considered more accurate than traditional methods. The goal of this study
was to compare mean tumor absorbed dose estimates using the unit density sphere model incorporated in
OLINDA with previously reported dose estimates from Monte Carlo simulations using the dose planning
method (DPMMC) particle transport algorithm. The dataset (57 tumors, 19 lymphoma patients who under-
went SPECT/CT imaging during I-131 radioimmunotherapy) included tumors of varying size, shape, and
contrast. OLINDA calculations were first carried out using the baseline tumor volume and residence time from
SPECT/CT imaging during 6 days post-tracer and 8 days post-therapy. Next, the OLINDA calculation was
split over multiple time periods and summed to get the total dose, which accounted for the changes in tumor
size. Results from the second calculation were compared with results determined by coupling SPECT/CT
images with DPM Monte Carlo algorithms. Results from the OLINDA calculation accounting for changes in
tumor size were almost always higher (median 22%, range - 1%–68%) than the results from OLINDA using
the baseline tumor volume because of tumor shrinkage. There was good agreement (median - 5%, range
- 13%–2%) between the OLINDA results and the self-dose component from Monte Carlo calculations, indi-
cating that tumor shape effects are a minor source of error when using the sphere model. However, because
the sphere model ignores cross-irradiation, the OLINDA calculation significantly underestimated (median
14%, range 2%–31%) the total tumor absorbed dose compared with Monte Carlo. These results show that
when the quantity of interest is the mean tumor absorbed dose, the unit density sphere model is a practical
alternative to Monte Carlo for some applications. For applications requiring higher accuracy, computer-
intensive Monte Carlo calculation is needed.
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Introduction
Radiolabeled antibody therapy, including I-131 radio-immunotherapy (RIT), has shown much success in the
treatment of malignancies such as non-Hodgkin’s lymphoma
(NHL).1,2 The potential exists to further improve the efficacy
of these therapies by individualized, dosimetry-based treat-
ment planning. Thus, there is much interest in the accurate
assessment of the radiation absorbed dose delivered to nor-
mal organs and tumor during therapy.
Conventionally, dosimetry in internal emitter therapy has
been based on the S-value formalism developed by the
Medical Internal Radiation Dose (MIRD) Committee.3 Here,
the absorbed dose to a target region from decays in a given
source region is expressed as the product of the cumulated
activity in the source region and the source-to-target S-value,
which is the absorbed dose to the target region per unit
cumulated activity in the source region. The total absorbed
dose to a target is then calculated as the sum of contribu-
tions from self-irradiation (where target and source regions
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are the same) and from cross-irradiation (where target and
source regions are different). The S-values for such calcula-
tions have been predetermined by Monte Carlo methods,
originally for the ‘‘Reference Man’’ anatomy4 and later for
stylized models representing individuals of both sexes at
several ages.5 A major limitation of using reference S-values
for absorbed dose estimation in patients is the potential for a
significant difference between organ geometries of the indi-
vidual patient and those of the models used to generate the
S-values. In addition, the models of the human anatomy
used to determine S-values do not include tumor, because
tumors can be of arbitrary shape, size, and location within
the anatomy.
For tumor dosimetry, the conventional approach has been
based on a sphere model that assumes that tumors are iso-
lated unit density spheres in an infinite unit density medium.
This approach has been implemented in the OLINDA/EXM
code,6 which is often used for dosimetry calculations in in-
ternal emitter therapy. For any of the radionuclides included
in the program, S-values for self-irradiation of unit density
spheres are available for discrete sphere masses in the range
0.01–6000 g. These S-values have been precalculated based
on the most recent evaluation of electron- and photon-
absorbed fractions in spheres of various sizes.7 Because
organ-to-tumor cross-dose depends almost exclusively on
the proximity of tumor relative to the organ and because
tumor locations are arbitrary, organ-to-tumor S-values can-
not be calculated for the general case. Therefore, dose esti-
mates from this approach will account only for the self-dose
and not for any cross-dose from any extratumor activity.
To overcome the obvious limitations of the simplistic
sphere model, researchers have turned to other more patient-
specific approaches to tumor dosimetry.8–13 One such ap-
proach is the dose point-kernel method, which is based on
convolving the spatial distribution of activity with tabulated
dose point-kernels for a specific isotope.14 This method tends
to be inaccurate when there are tissue inhomogeneities such
as at tissue–air and tissue–bone interfaces.14 Loudos et al.15
have recently developed a patient-specific dosimetry method
based on modifying tabulated dose point-kernels to account
for the spatial variation in densities (derived from patient
CTs) between source and target voxel centers. This method
was not considered in this work as it was felt that the in-
creased accuracy obtained by using a Monte Carlo-based
dosimetry model outweighed the relatively modest compu-
tation time penalty incurred.
The more sophisticated of the patient-specific tumor do-
simetry methods couples 3D anatomical (from MRI or CT)
and functional (from SPECT or PET) images of the patient
with explicit Monte Carlo radiation-transport calculations. In
a recent publication, highly patient-specific tumor dose as-
sessment results for 60 tumors in 20 NHL patients who un-
derwent I-131 tositumomab RIT were reported.12 Dose
assessment was carried out by coupling SPECT/CT imaging
data at multiple time points with the Dose Planning Method
Monte Carlo (DPMMC) radiation transport algorithm.13 The
voxel-level calculations were carried out, including deform-
able image registration to relate tumor voxels that are
changing from one time point to another because of tumor
regression or deformation. Registered tumor dose-rate maps
were integrated over time to obtain the 3D dose distribution,
which allowed for calculation of not only mean absorbed
dose to the tumor but also other summary measures such as
maximum dose and equivalent uniform dose. Such patient-
specific dose assessment provides 3D dose distributions and
is more accurate than a calculation based on reference S-
values. However, 3D imaging data are needed, in addition to
high computational requirements. With recent advances in
computer power and acceleration of Monte Carlo algorithms,
these calculations can be carried out in a research environ-
ment, but such calculations are still not practical for the
clinic. Therefore, when the quantity of interest is the mean
absorbed dose to the target, comparison of results from
patient-specific Monte Carlo calculations with results using
reference S-values is clinically relevant to determine the level
of accuracy that can be achieved with the simpler approach.
Previous reports on such comparisons have either focused on
organ dosimetry or were limited to simulated tumor geo
metries.16,17 The goal of the present study is to compare mean
tumor absorbed dose estimates using the unit sphere model
incorporated in OLINDA with dose estimates from previ-
ously reported Monte Carlo calculations for NHL patients.
Unlike previous reports, the present study uses actual patient
SPECT/CT imaging data and tumors of varying size, shape,
and uptake relative to background for this comparison.
Materials and Methods
Patient imaging data
The imaging data came from patients undergoing 131 I-
tositumomab therapy of relapsed or refractory B-cell lym-
phoma under an approved clinical protocol. The clinical
treatment protocol1 and the SPECT/CT imaging procedure
under a research protocol11,12 have been previously de-
scribed in detail and are summarized here. The administered
diagnostic (tracer) activity was 185MBq (5 mCi) and the
therapy activity ranged from 2.15 to 5.68 GBq (58–153 mCi).
For the research study, patients volunteered for imaging at
multiple time points on the Siemens Symbia TruePoint
SPECT/CT scanner. Patients were imaged three times fol-
lowing the tracer (days 0, 2, and 6) and three times following
the therapy (days 2, 5, and 7–9). At each time point, a nuclear
medicine specialist with radiology CT training defined the
tumor volumes of interests on CT, plane by plane. Data for
60 tumors in 20 patients (13 men and 7 women; age range,
33–81 years) were available for the present calculations. One
of these patients (patient 17 in Table 1), who developed
human anti-mouse antibodies, had too few SPECT counts to
perform dosimetry, so 19 patients with a total of 57 tumors
were analyzed.
Tumor time–activity curves
The 3D SPECT reconstruction and activity quantification
have been previously described11,12 and are summarized
here. SPECT data were reconstructed with 35 iterations (6
subsets) of 3D ordered-subsets expectations maximization
(OSEM) including triple-window-based scatter correction,
CT-based attenuation correction, and compensation for 3D
depth-dependent detector response. At each time point, the
SPECT counts within the CT-defined tumor volume were
converted to an activity using a calibration factor. Correction
for partial volume effects was carried out by applying volume-
dependent recovery coefficients determined from phantom
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experiments.12 Tumor time–activity data were generated for
both tracer and therapy administrations. For the present
study, the rest-of-the-body time–activity curves were not
needed, as only the self-dose is determined in the OLINDA
calculation. Time–activity data were fitted using a biexpo-
nential of the form A(t)¼ c  (e kat eket).18 This function was
analytically integrated over time to obtain the tumor residence
time (cumulated activity divided by the administered activity)
for the dosimetry calculations discussed later. The endpoint of
the integration was somewhat arbitrarily chosen as 300 hours.
The 300 hours time was selected, because the last imaging
time point was typically about 150 hours postadministration
for tracer and 190 hours postadministration for therapy and
extrapolating too far from that time point could lead to greater
variance in the results. The residence times when the time–
activity curve was integrated to infinity were within 5% of the
values obtained by integrating to 300 hours for every tumor
except one (patient 11, R psoas in Table 1). The activity
clearance of this tumor was unusually slow, resulting in a
residence time 53% higher when integrated to infinity. The
300 hours integration is consistent with the previous study in
which Monte Carlo dose-rate maps were integrated up to this
time to obtain the dose map.12
Although much emphasis was placed on accurate SPECT
activity quantification using state-of-the-art hybrid imaging
and 3D OSEM reconstruction, inaccuracies can remain be-
cause of approximations made when correcting for physical
factors, uncertainty in tumor volume determination, SPECT-
CT misregistration, and the limited imaging time points.
These inaccuracies will have a similar impact on the two
absorbed dose calculation methods compared in the present
work, because tumor time–activity data were generated in
the same manner for both calculations.
Tumor dosimetry using the unit density sphere model
For tumor dosimetry, the unit density sphere model im-
plemented within OLINDA was used. Here, tumors are
approximated as unit density spheres with uniformly dis-
tributed activity. The precalculated OLINDA sphere-model
S-factors for I-131 were obtained for all available sphere sizes
ranging from 0.01 to 6000 g. These S-values were plotted vs.
sphere mass and the fitted function was used to determine
the S-value for any mass. The dose equation based on the
MIRD formalism can be expressed as follows:
D¼ ~A  S¼A0  s  S (1)
Here, s is the residence time, A˜ is the cumulated activity, A0
is the patient’s administered activity, and S is the dose per
unit cumulated activity.
The dosimetry calculation was carried out with and
without accounting for changes in tumor size measured at
the multiple imaging time points. In the first approach, the
absorbed dose was estimated for a constant tumor mass
corresponding to the outline defined on the day 0 post-tracer
SPECT/CT (baseline mass). The tracer residence time was
determined by integrating the tracer time–activity curve
from 0 to 300 hours, and the therapy residence time was
determined by integrating the therapy time–activity curve
from 0 to 300 hours. To estimate the mean tumor absorbed
dose from the tracer administration, the S-value corre-
sponding to the baseline tumor mass and the tracer residence
time were used in Equation 1. To estimate the mean tumor
absorbed dose from the therapy administration, the S-value
corresponding to the baseline tumor mass and the therapy
residence time were used in Equation 1.
The availability of SPECT/CT imaging data and CT-
defined tumor outlines at multiple time points favor splitting
the OLINDA calculation over multiple time periods, which
was done in the second approach. As imaging was carried
out at three time points, three time periods were used for the
calculation. A typical tumor time–activity curve with the
three time periods (0 to t1, t1 to t2, t2 to 300 hours) is shown in
Figure 1. Here, T1, T2, and T3 are the three imaging time
points, t1 is the midpoint between T1 and T2, and t2 is the
midpoint between T2 and T3. The total dose was calculated




where s1, s2, and s3 are the residence times for the three time
periods determined by integrating the time–activity curve
over each period, and S1, S2, and S3 are the OLINDA S-
values corresponding to the tumor masses outlined at
imaging time points T1, T2, and T3, respectively. This calcu-
lation was carried out separately for the tracer and the
therapy imaging data.
The dosimetry results from the OLINDA calculation car-
ried out over multiple time periods according to Equation 2
were used for the comparison to the previous Monte Carlo
results as this approach is more consistent with how the
SPECT/CT data were previously utilized (SPECT/CT im-
ages and tumor outlines from each of the time points were
input to the DPMMC algorithm to generate corresponding
tumor dose-rate maps).12
Results
Typical patient SPECT/CT images with tumor outlines
are shown in Figure 2. The tumor dosimetry results for all
FIG. 1. A typical tumor time–activity curve showing the
biexponential fit and the three time periods used for the
OLINDA calculation over multiple time periods to account
for the measured changes in tumor size. The %ID is the
percentage of activity normalized by the injected activity.
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tumors are given in Table 1, together with other relevant
information useful for interpreting the dosimetry results. The
tumor-to-background activity concentration ratio, B, is the
activity per voxel in the tumor divided by the activity per
voxel in the rest of the body (‘‘rest of the body’’ was defined
as the total body section within the SPECT camera field of
view minus the tumor). Also given in Table 1 are the baseline
tumor volume defined on the first SPECT/CT and the de-
crease in tumor volume between this time point and the last
SPECT/CT time point. The study included a wide range of
tumor sizes (initial volume, 2–423mL), tumor locations, and
a wide range of B-values (2–19). Hence, there was a wide
range in the level of cross-irradiation. The mean tumor ab-
sorbed dose results given in Table 1 are the total delivered
from both the tracer and therapy administrations. Results
from the OLINDA calculation using a baseline tumor mass
and results from the OLINDA calculation carried out over
the multiple time periods, accounting for changes in tumor
mass, are given. Tumor absorbed doses calculated account-
ing for the mass changes were almost always higher than the
absorbed doses calculated assuming a baseline tumor mass.
The difference between the two OLINDA calculations ran-
ged from - 1% to 68%, with a median difference of 22%. The
mean absorbed dose accounting for mass change was sig-
nificantly higher than the mean absorbed dose without ac-
counting for this change ( p < 0.001, paired t-test).
Next, the comparison between the mean tumor absorbed
dose results from OLINDA and the previously reported
Monte-Carlo-based, patient-specific calculation is presented in
Table 1. (Note that results from the OLINDA calculation over
multiple time periods were used for this comparison.) OLIN-
DA results were compared with both the self-dose and the
total dose (sum of self-dose and cross-dose components) from
the Monte Carlo calculation. Almost always, the OLINDA
results were higher than the Monte Carlo self-dose, but only
slightly. Although the mean absorbed self-dose from OLINDA
was significantly higher than the mean absorbed self-dose
from Monte Carlo ( p< 0.001, paired t-test), the difference be-
tween these two calculations was small, ranging from - 13%
to 2%, with a median difference of only - 5%. The OLINDA
results were always lower than the Monte Carlo total dose,
and the difference between the two ranged from 2% to 31%,
with a median difference of 14%. The mean absorbed dose
from OLINDA was significantly lower than the mean ab-
sorbed total dose from Monte Carlo ( p< 0.001, paired t-test).
Discussion
For most of the 57 tumors, significant tumor shrinkage
was measured during the SPECT/CT imaging. Because of
the inverse relationship between absorbed dose and mass,
the OLINDA calculation carried out over multiple time pe-
riods gave significantly higher (up to 68%) absorbed doses
than the calculation assuming baseline tumor masses. Con-
ventionally, tumor dosimetry in internal emitter therapy has
been carried out assuming a constant tumor mass, typically
obtained from a diagnostic CT study performed before the
treatment. The present results demonstrate the inadequacy of
such an approach for dosimetry of malignant lymphoma,
which can have dramatic shrinkage within days of the
treatment.12,19 When tumor volume information from mul-
tiple time points is available, a reasonable approach is to
carry out the OLINDA calculation over multiple time peri-
ods as in the present study.
The unit density sphere model implemented within
OLINDA assumes all tumors are spherical, whereas the
DPM Monte Carlo calculation utilizes the actual tumor
contour outlined on CT. In all cases, the DPMMC self-dose
was lower than the OLINDA calculation, because in reality
tumors are nonspherical (see e.g., Fig. 2) and more beta
particles can escape from a nonspherical geometry without
depositing all of their energy compared with a spherical
geometry of the same volume. However, the relatively good
agreement between the OLINDA results and the DPMMC
self-dose results (see Table 1) shows that the sphere ap-
proximation is reasonable and shape effects are not a major
source of error. This is due to the I-131 beta emission, which
has a mean energy of 192 keV and has a short range
(2.3mm20 in water) compared to the size of the tumors of the
present dataset (smallest radius around 8mm, 16 times lar-
ger than the range of the beta particle). Shape effects may
lead to more errors in calculations for Y-90 RIT, which has a
higher energy beta emission (mean energy of 938 keV),
leading to a greater range in water (11.3mm20). In Table 1,
the comparison between OLINDA results and the total
DPMMC absorbed doses showed significant differences (up
to 31%). As expected, the total DPMMC dose was higher,
because the sphere model ignores the contribution from
FIG. 2. SPECT/CT images with outlines for inguinal tumor
(A), anterior iliac tumor (B, upper outline), and posterior iliac
tumor (B, lower outline). Images are for subject 10 in Table 1.
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1 Pelvis 400 5 3 125 129 - 5 18
2 Paraaortic 409 15 6 229 227 - 8 17
3 Inguinal 140 49 7 153 231 - 6 7
Iliac 234 45 7 140 218 - 9 5
4 Pelvis big 314 31 15 361 407 - 7 6
Pelvis small 39 27 14 380 387 - 5 10
5 Renal 58 62 4 246 274 - 5 23
L paraaortic 34 67 4 201 243 - 5 23
Central 21 50 4 222 252 - 5 27
Hepatic 19 62 3 210 263 - 5 28
Crux 10 57 4 164 234 - 4 26
6 L iliac 34 81 10 171 352 - 5 9
Paraaortic 74 65 9 160 335 - 10 13
7 R inguinal up 16 42 8 147 188 - 2 15
R inguinal big 71 37 9 190 235 - 5 10
R inguinal small 24 44 4 59 84 - 4 23
L inguinal up 11 39 9 129 183 - 1 12
L inguinal big 114 43 10 187 252 - 5 3
L inguinal small 22 55 7 100 164 - 3 14
8 R inguinal lateral 5 80 3 62 135 2 21
R inguinal medial 7 73 7 175 316 0 13
R iliac 54 77 6 161 296 - 8 13
R aorta 79 67 7 193 328 - 8 10
R anterior acetab. 34 87 7 148 332 - 6 11
R posterior acetab. 44 85 6 130 325 - 6 14
L acetabulum 31 79 7 142 355 - 5 16
9 R inguinal 12 46 4 63 93 - 2 18
L inguinal 19 28 4 71 85 - 3 16
L iliac 35 31 4 81 101 - 6 19
10 R anterior iliac 45 50 12 317 380 - 6 8
R posterior iliac 54 56 11 246 348 - 7 14
R inguinal 76 31 11 324 352 - 7 2
11 L kidney up 7 53 11 300 503 - 1 13
L kidney down 15 34 10 386 507 - 2 10
R psoas 113 7 10 508 536 - 7 5
12 Para vertebral 28 34 4 150 181 - 7 26
13 Hilar spleen 7 64 5 213 283 - 2 28
L Dph 36 60 3 154 215 - 5 28
L paraaortic 84 43 4 199 233 - 9 24
L psoas 36 39 3 171 200 - 8 20
R Dph down 6 35 4 164 209 - 4 31
R Dph up 27 49 3 167 210 - 5 29
R paraaortic 97 32 4 211 250 - 9 23
14 L neck up 3 20 5 175 180 - 1 16
L neck mid 2 11 7 245 255 0 13
L neck down 2 53 8 281 308 2 13
15 Central 18 40 5 233 334 - 7 27
16 Abdominal 423 18 3 144 150 - 5 24
17 Speen 157 25 NA NA NA NA NA
L pelvis 135 50 NA NA NA NA NA
L Ex 19 66 NA NA NA NA NA
18 Lung 151 81 2 53 167 - 6 30
19 L neck 12 41 4 221 354 - 13 13
20 L iliac 7 42 9 235 298 - 4 13
(continued)
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activity outside the sphere. In general, the difference between
results of DPMMC and OLINDA increases as the tumor-to-
background activity concentration ratio (B-value in Table 1)
decreases because of the increasing contribution from cross-
irradiation. There are, however, exceptions, because the
contribution to tumor dose from cross-irradiation depends
not only on the B-value but also on the size of the tumor and
the proximity of the tumor to structures with significant
uptake. As calculated, the B-value assumes a uniform ac-
tivity distribution in the rest of the body, but in reality there
is enhanced I-131 uptake in the liver, kidneys, spleen, and
heart. In addition, the contribution from cross-irradiation is
very much dependent on the photon energy, and hence, the
trends observed in the present I-131 study may not be ap-
plicable to therapies with other radionuclides.
In a previous study, the photon contribution to tumor
dose from I-131 activity outside the tumor was calculated by
Monte Carlo for simulated tumors positioned in the Re-
ference Man geometry.16 The underestimation of tumor dose
due to neglecting this contribution was found to be in the
range 10%–20%, which is comparable to the results of the
present study. In a more recent study, focusing mainly on
normal organ dosimetry Divoli et al.17 reported on the dif-
ferences between results obtained using patient-specific
Monte Carlo methodology and results obtained using the
reference S-values implemented in OLINDA. Individual
patient’s CT images (total of 9 patients) were used to define
the normal organs, whereas published biodistribution data
were used to assign cumulated activities. When a mass cor-
rection (available in OLINDA) was used to account for dif-
ferences in organ masses between the patient and the
standard model, good agreement (within 5%) was demon-
strated. For normal organs, agreement between the two
calculations can be expected to be better than the agreement
for tumor, because the cross-irradiation contribution is in-
cluded in the OLINDA calculation for normal organs. The
work by Divoli et al. also included tumor, but was limited to
two small (7 g each) spherical tumors, artificially placed in
the liver and the lung. The good agreement ( < 5%) between
Monte Carlo and OLINDA in that reported for tumor was
attributed to the limited nature of the study. Tumors of dif-
ferent size, shape, and varying levels of uptake relative to
background were not investigated as in the present work.
Conclusions
For NHL patients treated with I-131 tositumomab RIT, the
mean tumor absorbed doses determined using the unit
density sphere model in OLINDA were compared with
previously reported results from explicit Monte Carlo sim-
ulation using the DPMMC algorithm. SPECT/CT imaging
data from multiple time points were used in both calcula-
tions. The dataset included tumors of varying sizes and
shapes as well as varying uptake relative to the rest of the
body. There was good agreement when the OLINDA results
were compared with the self-dose component from the
Monte Carlo calculation, indicating that assuming a spherical
shape for the tumor was not a major source of error. How-
ever, because the sphere model ignores cross-irradiation, this
calculation significantly underestimated (median 14%, range
2%–31%) the total absorbed dose compared with Monte
Carlo. Although the tumor dosimetry calculation using the
sphere model is much more practical than the computer-
intensive Monte Carlo method, its level of accuracy may not
be acceptable for some treatment planning applications.
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L inguinal inferior 45 43 9 269 351 - 6 7
R iliac 12 32 19 630 670 - 1 6
R inguinal inferior 34 36 15 453 535 - 3 3
R inguinal lateral 5 30 9 263 311 2 15
R inguinal medial 14 57 13 340 493 0 7
R inguinal superior 5 53 7 159 246 2 17
aPercentage of difference in tumor volume defined on first post-tracer SPECT/CT and last post-therapy SPECT/CT (a time period
of approximately 15 days).
bTumor–to–rest-of-the-body activity concentration ratio.
cDifference calculated as 100· (Monte Carlo -OLINDA)/Monte Carlo.
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